Blue Blood Biotech Corp.

Quick facts

Phase 2 pipeline

• BB-101 · Oncology
  BB-101 is a small molecule that targets the PI3K pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Blue Blood Biotech Corp. portfolio CI brief
• Blue Blood Biotech Corp. pipeline updates RSS